Fort Lauderdale, Fla., Aug. 16, 2018 (GLOBE NEWSWIRE) -- In a milestone transaction, a major pharmaceutical company based in China will undertake a multisite clinical study using TrialMaster EDC Suite and Acuity Analytics, from OmniComm Systems, Inc., (OTCQX: OMCM), a leading global provider of clinical data management technology.
With eClinical solutions from OmniComm and related services, the pharmaceutical company will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial of a treatment for a well-known cognitive disorder. The trial represents the sponsor’s first use of TrialMaster and Acuity for a study. TrialMaster is the mobile-friendly, easy-to-use electronic data capture solution for Phase I - IV clinical trials. Acuity Analytics provides data aggregation, analytics and visualization tools.
OmniComm was selected based on TrialMaster’s inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process. Additionally, the pharmaceutical company selected Acuity because the product provides data visualization to manage the study and data analytics to make faster decisions.
“Building upon our significant traction in early phase trials, this award represents a major milestone for OmniComm, with a second sponsor in China this year now choosing to move to TrialMaster,” said Kuno van der Post, Ph.D., chief commercial officer from OmniComm. “Moreover, we are pleased with the selection of the Acuity data visualization tool, which is integrated with TrialMaster and can also support local languages.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. With an extensive global experience from more than 6,000 clinical trials, OmniComm provides comprehensive solutions for clinical research. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact InfoKuno van der Post, Ph.D. OmniComm Systems, Inc. +1.954.473.1254KvanderPost@omnicomm.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.